Four-year follow up data for Roche's Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk

Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMANinety-one percent of children were alive at month 48More than 95% maintained the...

Related Keywords

Switzerland ,Japan ,United Kingdom ,United States ,London ,City Of ,America ,British ,Kirti Pandey ,Loren Kalm ,Levi Garraway ,Birgit Masjost ,Nathalie Altermatt ,Bruno Eschli ,Gerard Tobin ,Sabine Borngr ,Giovanni Baranello ,British Pharmacological Society ,Roche Group ,Toddler Development Third Edition ,Drug Administration ,Research Clinical Care Meeting ,Head Of Global Product Development ,Society For Medicines Research ,Genentech ,Office Of Orphan Products Development ,European Medicines Agency ,Roche Group Media Relations ,Institute Of Child Health Hospital ,Gross Motor Scale ,Bayley Scales ,Hammersmith Infant Neurological Examination ,Clinical Care Meeting ,Ormond Street Institute ,Child Health ,Great Ormond Street Hospital ,Chief Medical Officer ,Global Product ,Orphan Drug Designation ,Drug Discovery ,Medicines Research ,Orphan Products Development ,Drug Designation ,Muscular Atrophy ,Spinal Muscular Atrophy ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,